Immunohistochemistry (IHC) staining of interferon (IFN)-λ in renal tissue The figure demonstrates a repeated renal biopsy obtained from a patient after.

Slides:

Advertisements

Similar presentations

Invest. Ophthalmol. Vis. Sci ;43(6): Figure Legend:

Advertisements

Transthoracic needle biopsy of lung adenocarcinoma: all tumour cells are stained with 5A4 clone (anaplastic lymphoma kinase (ALK) immunohistochemistry.

Ann Intern Med. 2015;162(1): doi: /M Figure Legend:

Volume 79, Issue 11, Pages (June 2011)

Anifrolumab inhibits cytokine production, plasmacytoid dendritic cell (pDC) activation and the type I (interferon gene signature) IFN gene signature. Anifrolumab.

Anifrolumab inhibits type I interferon (IFN)-induced IFN-stimulated response element (ISRE) signalling. Anifrolumab inhibits type I interferon (IFN)-induced.

Time between systemic lupus erythematosus (SLE) and haematological malignancy diagnoses. Time between systemic lupus erythematosus (SLE) and haematological.

Quiz Page December 2007 American Journal of Kidney Diseases

Volume 74, Issue 1, Pages (July 2008)

Time course for laboratory parameters of a patient with systemic lupus erythematosus prior and during bortezomib therapy (arrow). Time course for laboratory.

C.-W. Tsai, V.-C. Wu, W.-C. Lin, J.-W. Huang, M.-S. Wu

Fig. 2. GPC3 expression in normal and tumor tissues.

Fig. 5. Immunohistochemistry of the tumor microenvironment in GBM specimens before and after CART-EGFRvIII infusion. Immunohistochemistry of the tumor.

Volume 70, Issue 12, Pages (December 2006)

EULAR Lupus Nephritis Trials Network Study Group

Volume 77, Issue 9, Pages (May 2010)

Quiz Page December 2008 American Journal of Kidney Diseases

Volume 75, Issue 12, Pages (June 2009)

Mean Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score at the last.

Immunohistochemistry staining of interferon (IFN)-λ in renal tissue.

Association of AIM2, RIG‐I and NLRP3 inflammasomes with better survival in NPC patients.A.Overexpression of ASC, caspase‐1 and IL‐1β proteins as well as.

Volume 95, Issue 3, Pages (March 2019)

Lupus Foundation of America-Rapid Evaluation of Activity in Lupus (LFA-REAL) comprised seven anchored Visual Analogue Scales (0–100 mm each) and can describe.

TLR9 deficiency promotes aberrant T cell and myeloid dendritic cell (DC) phenotype in imiquimod-induced autoimmunity. TLR9 deficiency promotes aberrant.

Association of pretreatment interferon (IFN) signature metric (ISM) status with serum autoantibodies, BAFF levels and type I IFN bioactivity. Association.

Volume 62, Issue 2, Pages (August 2002)

Deficiency of TLR9 promotes more severe renal inflammation in imiquimod-induced autoimmunity. Deficiency of TLR9 promotes more severe renal inflammation.

Serum osteopontin (OPN) levels in population-based controls and in cases with SLE. Serum levels of OPN, determined by ELISA, were significantly higher.

The pattern of alteration of HCQ, prednisolone and/or ISS drugs by physicians in a patient with a history of major organ involvement from their SLE (renal.

Volume 69, Issue 10, Pages (May 2006)

No difference in T-cell response between SLE patients and healthy controls upon superantigen stimulation. No difference in T-cell response between SLE.

Receiver operating curve of soluble C3, C4, antibodies to double-stranded DNA (anti-dsDNA) compared with complement C4d levels on erythrocytes (EC4d) and.

Longitudinal changes in serum G3BP concentrations and SLEDAI in 15 patients with SLE. Each plot represents one patient. Longitudinal changes in serum G3BP.

Significant pathological changes and activation of Nrf2 pathway in the glomeruli of human diabetic nephropathy patients. Significant pathological changes.

SIRT1 is downregulated in human gastric cancer (GC).

Correlation between frequency of Th17 cells and disease activity or amount of proteinuria in patients with systemic lupus erythematosus (SLE). Correlation.

Correlation between mean Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI)

IGF1R is present in endometrial luminal epithelium at the receptive phase. IGF1R is present in endometrial luminal epithelium at the receptive phase. Endometrial.

Correlations between two measures of type I interferon activity and serum galectin-3-binding protein in the SLE-IFN-α (n=26) and HC-IFN-α (n=10) cohorts.

Celiac disease as a model for SLE

The effect of purified IgG from healthy controls or patients with lupus nephritis on tyrosine phosphorylation in podocytes at two different IgG concentrations.

Serum proteins dysregulated at baseline in patients enrolled in the MUSE study subsetted by IFNGS test status, Cutaneous Lupus Erythematosus Disease Area.

Tyrosine phosphorylation of proteins in podocyte lysates following exposure to healthy or lupus nephritis plasma. Tyrosine phosphorylation of proteins.

Attributed cause of end-stage renal disease (ESRD) among 251 patients with SLE in the Georgia Lupus Registry who progressed to ESRD (1979–2012), overall.

The role of IFN in viral infection over time

Comparison of the effects of growing podocytes in plasma from patients with lupus nephritis (LN), rheumatoid arthritis or non-renal lupus. Comparison of.

Hierarchical clustering of non-classical monocytes from patients and controls, with tracks indicating individuals, IFN score, SLEDAI score and prednisone.

Representative example of gating on T-cell subpopulations.

Distribution of the RAMRIS component scores sorted by pain score.

Presence of inpatient diagnostic codes for attributed cause of end-stage renal disease (ESRD) among 46 patients with systemic lupus erythematosus (SLE)

SLE deconvolution patient clusters and representative immune cell types (A), and distribution of patients by SLE deconvolution cluster and treatment group—all.

Fig. 5. Immunohistochemistry of the tumor microenvironment in GBM specimens before and after CART-EGFRvIII infusion. Immunohistochemistry of the tumor.

Proportion of patients consulting their general practitioner for symptoms within each British Isles Lupus Activity Group (BILAG) domain in the 5 years.

Immune cell populations associated with type I IFNGS test status and disease activity. Immune cell populations associated with type I IFNGS test status.

Serum anti-neuronal antibodies (anti-N) in patients with positive serum anti-GRP78. Serum anti-neuronal antibodies (anti-N) in patients with positive serum.

Plots showing the difference in expression rate versus the difference in averaged transcript amount between patients with SLE with SLEDAI ≥10 and those.

Mean change from baseline over time in BILAG score,

AXL is not expressed in human prostate tumors.

Overall gene expression in monocyte subsets in patients and controls.

(A) Mean urine protein/creatinine ratio (UPCR) and SEM in participants from the combined Lupus Nephritis Assessment of Rituximab (LUNAR) and A Study to.

IFN-γ-producing T-cells in SLE patients and healthy controls upon EBV antigen stimulation. IFN-γ-producing T-cells in SLE patients and healthy controls.

Activated T-cells in SLE patients and healthy controls upon EBV antigen stimulation. Activated T-cells in SLE patients and healthy controls upon EBV antigen.

Bronchial biopsy from patient 5 (a; Haematoxylin-Eosin-Safran stain and ×10 growth). Bronchial biopsy from patient 5 (a; Haematoxylin-Eosin-Safran stain.

Reduced klotho expression in pancreatic cancer.

Median percentage change in complement components 3 and 4 over time by SLE deconvolution cluster—all randomised and treated patients.* *Data from five.

TLR9 deficiency leads to more severe impairment of endothelium-dependent vasorelaxation and promotes aberrant B cell phenotype in imiquimod-induced autoimmunity.

Measures of endothelial activation/dysfunction are associated with QRISK3. Measures of endothelial activation/dysfunction are associated with QRISK3. Increased.

Relation of P-gp+CD69+CD4+ cells with outcome of intensive immunosuppressive therapy in patients with active proliferative lupus nephritis (LN). Relation.

Overall and recurrence-free survival.

(A–E) demonstrate a kidney biopsy from a patient with lupus nephritis (LN) class V. Representative micrographs: (A), an inflammatory infiltrate with T.

Presentation transcript:

Immunohistochemistry (IHC) staining of interferon (IFN)-λ in renal tissue The figure demonstrates a repeated renal biopsy obtained from a patient after immunosuppressive therapy and now lupus nephritis class II. The IHC staining for IFNλ is here sparse in t... Immunohistochemistry (IHC) staining of interferon (IFN)-λ in renal tissue The figure demonstrates a repeated renal biopsy obtained from a patient after immunosuppressive therapy and now lupus nephritis class II. The IHC staining for IFNλ is here sparse in tubular cells and not expressed in the glomeruli. Original magnifications: ×20. Agneta Zickert et al. Lupus Sci Med 2016;3:e000170 ©2016 by Lupus Foundation of America